1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Patient Monitoring Market Trends
  5. > World Continuous Glucose Monitoring Systems Market - Opportunities and Forecasts, 2014 - 2021

Continuous Glucose Monitoring (CGM) is one of the latest technological advancements in the field of diabetes management. CGM systems are a type of glucose monitoring devices that function by inserting a biosensor through transcutaneous or subcutaneous route. The embedded sensor measures the glucose levels in the interstitial fluid or in the blood and results are transmitted via a transmitter to a receiver/monitor that displays the results. CGM systems have emerged as an integral part of diabetes management owing to its several advantages over other glucose monitoring devices. Unlike conventional glucose monitors, these systems enable periodic monitoring of glucose levels, which is crucial to avoid any diabetic complications. In addition, CGMS technology has laid a roadmap to the most awaited, high-tech, closed-loop €˜artificial/bionic pancreas€™. Therefore, developing novel and technologically advanced CGMS is the prime focus of several glucose monitoring device manufacturing companies. CGMS offer a wide range of applications across all age-cohorts, healthcare settings (diagnostic centers/clinics, hospital ICUs and home healthcare) and geographies. Thus, CGMS market shows lucrative opportunity for both CGMS manufacturers and insulin pump manufacturers.The global CGMS market is forecast to reach $2.9 billion by 2021 registering a CAGR of 31.4% over the forecast period. The pipeline of high-tech CGMS devices, such as smartphone-connected CGMS, wearable and smartphone-connected CGMS, non-invasive CGMS and €˜smart€™ diabetes management solution (also called artificial/bionic pancreas), would result in larger adoption of CGMS among endocrinologists and patients.The market is categorized based on components, customer segments, end-user demographics and geographic regions. The CGMS components market includes durable components such as transmitters & receivers and integrated insulin pumps; and disposable components such as sensors. The segment for sensors occupies a dominant share in the CGMS market primarily due to the recurring sales of CGMS, short scrap life and bulk purchases. CGMS are deployed primarily by the diagnostic centers/clinics. Moreover, increasing usage of CGMS across the hospital ICUs and in-home healthcare settings has been observed. The CGMS devices market by age demographics is categorized as juveniles, Gen X and geriatrics. Detailed geographical analysis and segmentation is provided at country-level per-region€”North America (U.S., Canada and Mexico), Europe (U.K., France, Germany and others), Asia-Pacific (India, China and Australia) and LAMEA (Gulf Cooperation Council). Key market players include Medtronic plc, Dexcom, Inc., Abbott Diabetes Care, Animas Corporation, including others. The major strategies adopted by the market players across geographies are collaborations, product launches and approvals. Collaborations in the regions focus on innovation, distribution and commercialization of the devices.

KEY BENEFITS
In-depth and country-level analysis within all the geographic regions would provide a clear understanding of current and future trends in the CGMS marketComprehensive analysis of factors that drive and restrict the growth of the CGMS market is providedThe report covers detailed quantitative analysis of the current market and estimations through 2014€“2021, which would enable the stakeholders to capitalize on prevailing market opportunitiesA detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation An in-depth analysis of current research and clinical developments within CGMS market is provided with key market dynamic factors that help in understanding the behavior of market Key market players within the CGMS market are profiled in the report and their strategies are analyzed thoroughly, which help in understanding the competitive outlook of the global CGMS market 

KEY MARKET SEGMENTS
The CGMS market is segmented based on components, customer segments, end-user demographics and geography (country-level). Global CGMS Market - by ComponentsSensors Transmitters & Receivers Integrated insulin pumps Global CGMS Market - by Customer SegmentsDiagnostics/ClinicICUsHome HealthcareGlobal CGMS Market - by End-user DemographicsJuvenilesGen XGeriatrics/undiagnosedGlobal CGMS Market - by GeographyNorth America United StatesCanadaMexicoEuropeUnited KingdomGermanyFranceOthersAsia-PacificChinaIndiaAustraliaOthersLAMEAGulf Cooperation Council (GCC)Others

Table Of Contents

World Continuous Glucose Monitoring Systems Market - Opportunities and Forecasts, 2014 - 2021
TABLE OF CONTENTSCHAPTER 1 INTRODUCTION1.1 Report description1.2 Key benefits1.3 Key market segment1.4 Research methodology1.4.1 Secondary research1.4.2 Primary research1.4.3 Analyst tools and modelsCHAPTER 2 EXECUTIVE SUMMARYCHAPTER 3 MARKET OVERVIEW3.1 Market definition3.2 Need for glucose monitoring systems3.2.1 Diabetes andeuro;andldquo; a pandemic3.2.1.1 Type 1 diabetes3.2.1.2 Type-2 diabetes3.2.1.3 Pre-diabetes and Gestational Diabetes Mellitus (GDM)3.2.1.4 Gestational Diabetes Mellitus (GDM)3.2.1.5 Secondary diabetes3.2.2 Global healthcare expenditure on diabetes3.3 Emerging technologies in CGMS3.3.1 Smartphone-connected CGMS3.3.2 Wearable and smartphone-connected CGMS3.3.3 Non-invasive CGMS3.3.4 Invasive CGMS in the Randamp;D pipeline3.3.5 and#39;Smartandeuro;andtrade; diabetes management solution andeuro;andldquo; Bionic Pancreas3.4 CGMS - Prime end user segments3.4.1 CGMS andeuro;andldquo; crucial need in Intensive Care Units (ICUs)3.4.1.1 andeuro;andtilde;Stress Hyperglycemiaandeuro;andtrade; andeuro;andldquo; common occurrence in ICUs3.4.1.2 Non-standardization and erroneous glycemic control across ICUs3.4.2 Benefits and factors driving adoption of CGMS in ICUs3.4.2.1 CGMS aid in Tight Glycemic Control in ICUs3.4.2.2 Cost benefits from usage of CGMS3.4.2.3 POC Glucometers less effective in ICUs - as compared to CGMS3.4.2.4 CGMS andeuro;andldquo; most preferred by ICU staff3.5 Key findings3.5.1 Top impacting factors3.5.2 Top investment pockets3.5.2.1 CGMS market andeuro;andldquo;By End User Segments3.5.2.2 CGMS market andeuro;andldquo; by geography3.5.3 Top winning strategies3.6 Value chain analysis3.7 Market share analysis, 20143.8 Government regulations3.9 Reimbursement scenario3.10 Drivers3.10.1 Rise in incidence of diabetes globally3.10.2 Inherent benefits of CGMS over POC glucometers andeuro;andldquo; drive market growth3.10.3 Increase in awareness in developing and underdeveloped economies3.10.4 Focus on developing OTC/POC CGMS catering to new end user segment - future growth driver3.10.5 FDA, U.S. approval of Bionic Pancreas andeuro;andldquo; future growth driver3.11 Restraints3.11.1 Stringent regulatory requirements3.11.2 Inadequate reimbursementsandeuro;andrdquo;a barrier in CGMS adoption3.11.3 Accuracy and costandeuro;andrdquo;a hindrance in continuing use of CGMS3.12 Opportunities3.12.1 Higher adoption rate of CGMS in ICUs3.12.2 OTC/POC CGMS - expanded product applications/usage3.12.3 andeuro;andtilde;Undiagnosedandeuro;andtrade; patient population3.13 Winning strategies for MNCs for entering emerging markets3.13.1 Gaining CE approvals for a speedier entry into Asia--Pacific and LAMEA markets3.13.2 Forming distribution alliances to enhance geographical reach3.13.3 Raising end-user awareness and competitive product pricingCHAPTER 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY COMPONENTS4.1 Stand-alone and Integrated CGM systems4.1.1 Market size and forecast4.2 Sensors4.2.1 Key market trends4.2.1.1 Non-invasive glucose sensors4.2.1.2 Subcutaneous sensors (Minimally Invasive Sensors)4.2.1.3 Conventional technologyandeuro;andrdquo;holter-yype retrospective sensors4.2.1.4 Advanced technologyandeuro;andrdquo;Real-Time sensors4.2.2 Key growth factors and opportunities4.2.3 Market size and forecast4.3 Transmitters andamp; Receivers4.3.1 Key market trends4.3.2 Key growth factors and opportunities4.3.3 Market size and forecast4.4 Integrated Insulin pumps4.4.1 Overview4.4.2 Key market trends4.4.3 Key growth factors and opportunities4.4.4 Market size and forecastCHAPTER 5 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY END USER SEGMENT5.1 Market size and forecast5.2 Diagnostic centers/clinics5.2.1 Market size and forecast5.3 ICUs5.3.1 Market size and forecast5.4 Home healthcare5.4.1 Market size and forecastCHAPTER 6 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET andeuro;andldquo; BY AGE DEMOGRAPHICS6.1 Juveniles6.2 Gen X6.3 Geriatrics / undiagnosedCHAPTER 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY GEOGRAPHY7.1 North America7.1.1 Market size and forecast7.1.2 U.S.7.1.3 Canada7.1.4 Mexico7.2 Europe7.2.1 Key market trends7.2.2 Key growth factors and opportunities7.2.4 France7.2.4.1 Key market trends7.2.4.2 Key growth factors and opportunities7.2.5 Germany7.2.5.1 Key market trends7.2.5.2 Key growth factors and opportunities7.2.6 U.K.7.2.6.1 Key market trends7.2.6.2 Key growth factors and opportunities7.2.7 Other European countries7.3 Asia-Pacific7.3.1 Market size and forecast7.3.2 India7.3.2.1 Key market trends7.3.3 Australia7.3.3.1 Key market trends7.3.4 China7.3.4.1 Key market trends7.3.5 Other APAC countries7.4 LAMEA7.4.1 Overview7.4.2 Market size and forecast7.4.3 Gulf Cooperation Council (GCC)7.4.3.1 Key market trendsCHAPTER 8 COMPANY PROFILES8.1 Medtronic Plc.8.1.1 Company overview8.1.2 Business performance8.1.3 Strategic moves and developments8.1.3.1 Principal strategies: product launch8.1.3.2 Secondary strategies: approval8.1.3.3 Other strategies: strategic alliance and collaboration8.1.4 SWOT analysis of Medtronic Plc8.2 Dexcom Inc.8.2.1 Company overview8.2.2 Business performance8.2.3 Strategic moves and developments8.2.3.1 Principal strategies: agreement/partnership8.2.3.2 Secondary strategies: approval8.2.3.3 Other strategies: acquisition8.2.4 SWOT analysis of Dexcom8.3 Abbott Diabetic Care (Abbott Laboratories)8.3.1 Company overview8.3.2 Business performance8.3.3 Strategic moves and developments8.3.4 SWOT analysis of Abbott diabetic care8.4 Animas Corporation8.4.1 Company overview8.4.2 Strategic moves and developments8.4.3 SWOT analysis of Animas Corporation8.5 Echo Therapeutics8.5.1 Company Overview8.5.2 Strategic moves and development8.5.3 SWOT Analysis of Echo Therapeutics8.6 Insulet Corporation8.6.1 Company overview8.6.2 Strategic moves and developments8.6.3 SWOT analysis of INSULET Corporation8.7 Glysens Inc.8.7.1 Company overview8.7.2 Strategic moves and developments8.7.3 SWOT Analysis of Glysens Inc.8.8 Senseonics, Inc.8.8.1 Company overview8.8.2 Strategic moves and development8.8.3 SWOT analysis of Senseonics, Inc.LIST OF FIGURESFIG. 1 PREVALENCE OF TYPE 1 DIABETES (AGED andlt;15 YEARS), BY GEOGRAPHYFIG. 2 GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)FIG. 3 PREDISPOSITION AND RISK FACTORS andeuro;andldquo; SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETESFIG. 4 GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20andeuro;andldquo;79 YEARS)FIG. 5 GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHYFIG. 6 OCCURENCE OF HYPERGLYCEMIA IN ICUSFIG. 7 TOP FACTORS IMPACTING CGMS MARKET, 2014-2021FIG. 8 TOP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETSFIG. 9 TOP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETSFIG. 10 TOP WINNING STRATEGIES IN CGMS MARKET, 2010 - 2014FIG. 11 TOP WINNING STRATEGY IN CGMS MARKET BY YEAR, 2010andeuro;andldquo;2014 (SEPTEMBER)FIG. 13 MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET 2014FIG. 14 GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)FIG. 15 PATIENT POPULATION UNDIAGNOSED FOR DIABETES , 2013 (MILLION)FIG. 16 GLOBAL CGMS MARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021FIG. 17 CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)FIG. 18 CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)FIG. 19 MEDTRONIC REVENUE BY GEOGRAPHY (2014)FIG. 20 SWOT ANALYSIS OF MEDTRONIC PLCFIG. 21 SWOT ANALYSIS OF DEXCOM INC.FIG. 22 REVENUE BY BUSINESS SEGMENT (2014)FIG. 23 SWOT ANALYSIS OF ABBOTT DIABETIC CAREFIG. 24 SWOT ANALYSIS OF ANIMAS CORPORATIONFIG. 25 SWOT ANALYSIS OF ECHO THERAPEUTICSFIG. 26 SWOT ANALYSIS OF INSULET CORPORATIONFIG. 27 SWOT ANALASIS OF GLYSEN INCORPORATEDFIG. 28 SWOT ANALYSIS OF SENSEONICS, INC.LIST OF TABLETABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2014)TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2013)TABLE 3 GLOBAL CGM MARKET BY COMPONENTS, 2014-2021 ($MILLION)TABLE 4 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2014andeuro;andldquo;2021 ($MILLION)TABLE 5 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)TABLE 6 GLOBAL CGM INTEGRATED INSULIN PUMPS MARKET BY GEOGRAPHY, 2014andeuro;andldquo;2021 ($MILLION)TABLE 7 GLOBAL CGM MARKET BY END USER SEGMENT, 2014-2021 ($MILLION)TABLE 8 GLOBAL CGM DIAGNOSTIC CENTRES/CLINICS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)TABLE 9 GLOBAL CGM ICUS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)TABLE 10 GLOBAL CGM HOME HEALTHCARE MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)TABLE 11 TYPE-1 DIABETES (0-14 YEARS), 2013TABLE 12 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2014 AND 2021TABLE 13 GLOBAL CGMS BY GEOGRAPHY, 2014-2021 ($MILLION)TABLE 14 NORTH AMERICA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)TABLE 15 NORTH AMERICA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPETABLE 18 EUROPE CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)TABLE 19 TOP 10 COUNTRIES WITH DIABETES INCIDENCE 2013 AND 2035TABLE 20 PREVALENCE ESTIMATES OF DIABETES, 2013 AND 2035TABLE 21 APAC CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)TABLE 22 APAC CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)TABLE 23 MEDICAL DEVICES USED IN AUSTRALIATABLE 24 LAMEA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)TABLE 25 LAMEA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)TABLE 26 MEDTRONIC BUSINESS SNAPSHOTTABLE 27 MEDTRONIC REVENUE BY BUSINESS UNITS (2014)TABLE 28 DEXCOM INC. BUSINESS SNAPSHOTTABLE 29 ABBOTT DIABETIC CAREBUSINESS SNAPSHOTTABLE 30 ANIMAS CORPORATION BUSINESS SNAPSHOTTABLE 31 ECHO THERAPEUTICS COMPANY SNAPSHOTTABLE 32 INSULET CORPORATION BUSINESS SNAPSHOTTABLE 33 GLYSENS INC. BUSINESS SNAPSHOTTABLE 34 SENSEONICS, INC. SNAPSHOT

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
North America Glucose Monitoring Market Outlook to 2022

North America Glucose Monitoring Market Outlook to 2022

  • $ 5995
  • Industry report
  • January 2017
  • by GlobalData

North America Glucose Monitoring Market Outlook to 2022 Summary GlobalData’s new report, "North America Glucose Monitoring Market Outlook to 2022", provides key market data on the North America Glucose ...

Asia-Pacific Glucose Monitoring Market Outlook to 2022

Asia-Pacific Glucose Monitoring Market Outlook to 2022

  • $ 5995
  • Industry report
  • January 2017
  • by GlobalData

Asia-Pacific Glucose Monitoring Market Outlook to 2022 Summary GlobalData’s new report, "Asia-Pacific Glucose Monitoring Market Outlook to 2022", provides key market data on the Asia-Pacific Glucose ...

EU5 Glucose Monitoring Market Outlook to 2022

EU5 Glucose Monitoring Market Outlook to 2022

  • $ 5995
  • Industry report
  • January 2017
  • by GlobalData

EU5 Glucose Monitoring Market Outlook to 2022 Summary GlobalData’s new report, "EU5 Glucose Monitoring Market Outlook to 2022", provides key market data on the EU5 Glucose Monitoring market. The report ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.